Rapid cell culture and pre-clinical screening of a transforming growth factor-Β (TGF-Β) inhibitor for orthopaedics

BMC Musculoskeletal Disorders

Volumn 11, Issue , 2010, Pages

  Schindeler, Aaron ^a,b   Morse, Alyson ^a   Peacock, Lauren ^a   Mikulec, Kathy ^a   Yu, Nicole Y C ^a,c   Liu, Renjing ^a,b   Kijumnuayporn, Sandy ^a,b   McDonald, Michelle M ^a   Baldock, Paul A ^d   Ruys, Andrew J ^c   Little, David G ^a,b  

^a CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

^b University of Sydney   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; ALKALINE PHOSPHATASE; ALPHA TUBULIN; BIOLOGICAL MARKER; BONE MORPHOGENETIC PROTEIN 2; POLYMER; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; SMAD PROTEIN; SMAD1 PROTEIN; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 1; TRANSFORMING GROWTH FACTOR BETA1; 1,3 DIOXOLANE DERIVATIVE; 4 (5 BENZO(1,3)DIOXOL 5 YL 4 PYRIDIN 2 YL 1H IMIDAZOL 2 YL)BENZAMIDE; 4-(5-BENZO(1,3)DIOXOL-5-YL-4-PYRIDIN-2-YL-1H-IMIDAZOL-2-YL)BENZAMIDE; BENZAMIDE DERIVATIVE; BMP2 PROTEIN, MOUSE; RUNX2 PROTEIN, MOUSE; TRANSCRIPTION FACTOR RUNX2;

ALP GENE; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BONE DEVELOPMENT; BONE MATRIX; BONE MINERALIZATION; BONE REMODELING; CELL CULTURE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG EFFECT; DRUG MEGADOSE; DRUG SCREENING; FEMUR; GENE; GENE EXPRESSION; HINDLIMB; IN VIVO STUDY; LOW DRUG DOSE; MOUSE; NONHUMAN; OCN GENE; OSSIFICATION; OSTEOBLAST; PROTEIN PHOSPHORYLATION; RUNX2 GENE; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; CELL LINE; CULTURE TECHNIQUE; DISEASE MODEL; DRUG ANTAGONISM; GENETICS; METABOLISM; METHODOLOGY; ORTHOPEDIC SURGERY; PHYSIOLOGY;

ANIMALS; BENZAMIDES; BONE MORPHOGENETIC PROTEIN 2; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL LINE; CELLS, CULTURED; CORE BINDING FACTOR ALPHA 1 SUBUNIT; DIOXOLES; DISEASE MODELS, ANIMAL; MICE; MICE, INBRED C57BL; ORTHOPEDIC PROCEDURES; OSTEOGENESIS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA1;

EID: 77952696475     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-11-105     Document Type: Article

References (34)

1. Mechanism for the action of bone morphogenetic proteins and regulation of their activity. S Ebara K Nakayama, Spine (Phila Pa 1976) 2002 27 10 S15 12205413
2. Signal transduction by bone morphogenetic proteins. M Kawabata T Imamura K Miyazono, Cytokine Growth Factor Rev 1998 9 49 61 10.1016/S1359-6101(97)00036- 1 9720756 (Pubitemid 28280536)
3. Specificity and versatility in tgf-beta signaling through Smads. XH Feng R Derynck, Annu Rev Cell Dev Biol 2005 21 659 693 10.1146/annurev.cellbio.21. 022404.142018 16212511
4. Extracellular control of TGFbeta signalling in vascular development and disease. P ten Dijke HM Arthur, Nat Rev Mol Cell Biol 2007 8 857 869 10.1038/nrm2262 17895899
5. Differential temporal expression of members of the transforming growth factor beta superfamily during murine fracture healing. TJ Cho LC Gerstenfeld TA Einhorn, J Bone Miner Res 2002 17 513 520 10.1359/jbmr.2002.17.3.513 11874242
6. Fracture healing as a post-natal developmental process: molecular, spatial, and temporal aspects of its regulation. LC Gerstenfeld DM Cullinane GL Barnes DT Graves TA Einhorn, J Cell Biochem 2003 88 873 884 10.1002/jcb.10435 12616527
7. Effects of transforming growth factor-beta 1 (TGF-beta1) on in vitro mineralization of human osteoblasts on implant materials. H Zhang M Ahmad G Gronowicz, Biomaterials 2003 24 2013 2020 10.1016/S0142-9612(02)00616-6 12628820
8. Bone defect repair in rat tibia by TGF-beta1 and IGF-1 released from hydrogel scaffold. S Srouji I Blumenfeld A Rachmiel E Livne, Cell Tissue Bank 2004 5 223 230 10.1007/s10561-004-0503-7 15591825
9. The effect of transforming growth factor beta1 (TGF-beta1) on the regenerate bone in distraction osteogenesis. K Ozkan L Eralp M Kocaoglu B Ahishali B Bilgic Z Mutlu M Turker FU Ozkan K Sahin M Guven, Growth Factors 2007 25 101 107 10.1080/08977190701352594 17891595
10. Transforming growth factor-beta isoforms and the induction of bone formation: implications for reconstructive craniofacial surgery. U Ripamonti C Ferretti J Teare L Blann, J Craniofac Surg 2009 20 1544 1555 10.1097/SCS.0b013e3181b09ca6 19816294
11. TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. T Alliston L Choy P Ducy G Karsenty R Derynck, EMBO J 2001 20 2254 2272 10.1093/emboj/20.9. 2254 11331591
12. Repression of Runx2 function by TGF-beta through recruitment of class II histone deacetylases by Smad3. JS Kang T Alliston R Delston R Derynck, EMBO J 2005 24 2543 2555 10.1038/sj.emboj.7600729 15990875
13. Inhibition of osteogenic differentiation of human mesenchymal stem cells. EK Moioli L Hong JJ Mao, Wound Repair Regen 2007 15 413 421 10.1111/j.1524-475X.2007.00244.x 17537129
14. Transforming growth factor-beta 1 stimulates chondrogenesis and inhibits osteogenesis in high density culture of periosteum-derived cells. M Iwasaki K Nakata H Nakahara T Nakase T Kimura K Kimata AI Caplan K Ono, Endocrinology 1993 132 1603 1608 10.1210/en.132.4.1603 8462458
15. The effect of exogenous transforming growth factor-beta 2 on healing fractures in the rabbit. MA Critchlow YS Bland DE Ashhurst, Bone 1995 16 521 527 10.1016/8756-3282(95)00085-R 7654467
16. Effects of locally applied transforming growth factor-beta1 on distraction osteogenesis in a rabbit limb-lengthening model. F Rauch D Lauzier R Travers F Glorieux R Hamdy, Bone 2000 26 619 624 10.1016/S8756-3282(00)00283-0 10831934
17. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. RD Cohn C van Erp JP Habashi AA Soleimani EC Klein MT Lisi M Gamradt CM ap Rhys TM Holm BL Loeys F Ramirez DP Judge CW Ward HC Dietz, Nat Med 2007 13 204 210 10.1038/nm1536 17237794
18. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. JP Habashi DP Judge TM Holm RD Cohn BL Loeys TK Cooper L Myers EC Klein G Liu C Calvi M Podowski ER Neptune MK Halushka D Bedja K Gabrielson DB Rifkin L Carta F Ramirez DL Huso HC Dietz, Science 2006 312 117 121 10.1126/science.1124287 16601194
19. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. DS Lim S Lutucuta P Bachireddy K Youker A Evans M Entman R Roberts AJ Marian, Circulation 2001 103 789 791 11171784
20. Rationale and design of a randomized clinical trial of beta-blocker therapy (atenolol) versus angiotensin II receptor blocker therapy (losartan) in individuals with Marfan syndrome. RV Lacro HC Dietz LM Wruck TJ Bradley SD Colan RB Devereux GL Klein JS Li LL Minich SM Paridon GD Pearson BF Printz RE Pyeritz E Radojewski MJ Roman JP Saul MP Stylianou L Mahony Pediatric Heart Network Investigators, Am Heart J 2007 154 624 631 10.1016/j.ahj.2007.06.024 17892982
21. Chronic treatment with angiotensin AT1 receptor antagonists reduced serum but not bone TGF-beta1 levels in ovariectomized rats. YQ Li H Ji Y Shen LJ Ding P Zhuang YL Yang QJ Huang, Can J Physiol Pharmacol 2009 87 51 55 10.1139/Y08-097 19142215
22. SB-431542 is a potent and specific inhibitor of transforming growth factor-beta superfamily type I activin receptor-like kinase (ALK) receptors ALK4, ALK5, and ALK7. GJ Inman FJ Nicolas JF Callahan JD Harling LM Gaster AD Reith NJ Laping CS Hill, Mol Pharmacol 2002 62 65 74 10.1124/mol.62.1.65 12065756
23. Endogenous TGF-beta signaling suppresses maturation of osteoblastic mesenchymal cells. S Maeda M Hayashi S Komiya T Imamura K Miyazono, EMBO J 2004 23 552 563 10.1038/sj.emboj.7600067 14749725
24. Dimethyl sulfoxide as an inducer of differentiation in preosteoblast MC3T3-E1 cells. WM Cheung WW Ng AW Kung, FEBS Lett 2006 580 121 126 10.1016/j.febslet.2005.11.062 16360153
25. Modeling bone morphogenetic protein and bisphosphonate combination therapy in wild-type and Nf1 haploinsufficient mice. A Schindeler M Ramachandran C Godfrey A Morse M McDonald K Mikulec DG Little, J Orthop Res 2008 26 65 74 10.1002/jor.20481 17787010
26. Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro. A Schindeler DG Little, Biochem Biophys Res Commun 2005 338 710 716 10.1016/j.bbrc.2005.09.198 16243296
27. Myoblast sensitivity and fibroblast insensitivity to osteogenic conversion by BMP-2 correlates with the expression of Bmpr-1a. R Liu SL Ginn M Lek KN North IE Alexander DG Little A Schindeler, BMC Musculoskelet Disord 2009 10 51 10.1186/1471-2474-10-51 19442313
28. Replacement of bone marrow by bone in rat femurs: the bone bioreactor. Q Zhang E Cuartas N Mehta J Gilligan HZ Ke WM Saltzman M Kotas M Ma S Rajan C Chalouni J Carlson A Vignery, Tissue Eng Part A 2008 14 237 246 10.1089/tea.2007.0261 18333776
29. Biglycan-deficient mice have delayed osteogenesis after marrow ablation. XD Chen MR Allen S Bloomfield T Xu M Young, Calcif Tissue Int 2003 72 577 582 10.1007/s00223-002-1101-y 12724831
30. Serial passage of MC3T3-E1 cells alters osteoblastic function and responsiveness to transforming growth factor-beta1 and bone morphogenetic protein-2. CY Chung A Iida-Klein LE Wyatt GH Rudkin K Ishida DT Yamaguchi TA Miller, Biochem Biophys Res Commun 1999 265 246 251 10.1006/bbrc.1999.1639 10548521
31. Effect of serial passage on gene expression in MC3T3-E1 preosteoblastic cells: a microarray study. W Huang B Carlsen GH Rudkin N Shah C Chung K Ishida DT Yamaguchi TA Miller, Biochem Biophys Res Commun 2001 281 1120 1126 10.1006/bbrc.2001.4458 11243851
32. Transforming growth factor-beta in the brain regulates fat metabolism during endurance exercise. T Ishikawa W Mizunoya T Shibakusa K Inoue T Fushiki, Am J Physiol Endocrinol Metab 2006 291 1151 E1159 10.1152/ajpendo.00039.2006 16822963
33. Transforming growth factor beta 2 promotes the formation of the mouse cochleovestibular ganglion in organ culture. J Okano T Takigawa K Seki S Suzuki K Shiota M Ishibashi, Int J Dev Biol 2005 49 23 31 10.1387/ijdb.041905jo 15744664
34. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Y Tang X Wu W Lei L Pang C Wan Z Shi L Zhao TR Nagy X Peng J Hu X Feng W Van Hul M Wan X Cao, Nat Med 2009 15 757 765 10.1038/nm.1979 19584867